Alector Company
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.
Investors
Technology:
Biotechnology, Genetics, Health Care, Therapeutics
Industry:
End-to-end Drug Development
Headquarters:
San Francisco, California, United States
Founded Date:
2013-01-01
Employees Number:
101-250
Funding Status:
IPO
Investors Number:
20
Total Funding:
194500000
Estimated Revenue:
$10M to $50M
Last Funding Date:
2018-07-25
Last Funding Type:
Series E
Register and Claim Ownership